PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity
Authors:
- 9 November 2019
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 85 (1) , 225-229
Abstract
The purpose of this study was to determine the importance of UGT1A1 activity on the metabolism and pharmacokinetics of a releasable PEG ~ SN-38 conjugate, PLX038A. Irinotecan (CPT-11) is converted to the topoisomerase 1 inhibitor SN-38 by first-pass hepatic metabolism and is converted to its glucuronide SN-38G by UGT1A1. With diminished UGT1A1 activity, the high liver exposure to SN-38 can cause increased toxicity of CPT-11. In contrast, releasable PEG ~ SN-38 conjugates—such as PLX038—release SN-38 in the vascular compartment, and only low levels of SN-38 are expected to enter the liver by transport through the OATP1B1 transporter.Keywords
This publication has 12 references indexed in Scilit:
- UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practiceFundamental & Clinical Pharmacology, 2015
- Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer modelsCancer Chemotherapy and Pharmacology, 2014
- Macromolecular Prodrug That Provides the Irinotecan (CPT-11) Active-Metabolite SN-38 with Ultralong Half-Life, LowCmax, and Low Glucuronide FormationJournal of Medicinal Chemistry, 2014
- Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in HumansPharmaceutical Research, 2013
- Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugatesProceedings of the National Academy of Sciences, 2012
- Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) LinkersBioconjugate Chemistry, 2008
- Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in ratsCancer Chemotherapy and Pharmacology, 2007
- Novel SN-38–Incorporating Polymeric Micelles, NK012, Eradicate Vascular Endothelial Growth Factor–Secreting Bulky TumorsCancer Research, 2006
- Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic DysfunctionClinical Cancer Research, 2006
- UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityThe Pharmacogenomics Journal, 2002